公开(公告)号：US10933134B2

公开(公告)日：2021-03-02

申请号：US15924039

申请日：2018-03-16

申请人： Memorial Sloan Kettering Cancer Center ,  Yeda Research and Development Co. Ltd., at the Weizmann Institute of Science

发明人： Jonathan Coleman ,  Philip A. Watson ,  Kwanghee Kim ,  Avigdor Scherz

IPC分类号： A61K41/00 ,  A61P35/00 ,  A61K31/4166 ,  A61K38/08 ,  A61K47/64 ,  A61N5/06

摘要： A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).

公开(公告)号：US11278555B2

公开(公告)日：2022-03-22

申请号：US16092742

申请日：2017-04-10

申请人： Yeda Research and Development Co. Ltd. ,  Memorial Sloan-Kettering Cancer Center

发明人： Avigdor Scherz ,  Yoram Salomon ,  Lilach Agemy ,  Rachel Hamri ,  Dina Preise ,  Kwanghee Kim ,  Jonathan Coleman

IPC分类号： A61K31/675 ,  A61K31/409 ,  A61K31/7068 ,  A61K31/7135 ,  A61K45/06 ,  A61P35/00

摘要： An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter “Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).